Drug Development Pipeline
LAU-7b is an oral compound. It is a form of the retinoid fenretinide. Retinoids are a group of compounds related to vitamin A. LAU-7b was studied for its potential to reduce the inflammatory response in the lungs of people with CF.
A phase 2 study to test the safety and effectiveness of LAU-7b in people with CF was completed.
This program is sponsored by Laurent Pharmaceuticals. It was conducted within the Therapeutics Development Network.
Recent LAU-7b Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More